2 results
Approved WMORecruitment started
In the RAINBO POLEmut-BLUE trial, omission of adjuvant therapy will be investigated in very low risk disease and de-escalation of treatment (observation or radiotherapy, but not chemoradiation) in low risk disease.
Approved WMOPending
This study aims to determine the effect of real-time symptom monitoring on HRQoL in patients with mBC who start first-line chemo(immune)therapy. Further objectives include analyzing the effect of PRS monitoring on physical functioning, the severity…